SEA LTD

Evotec launches J.TRAIN, a modular, cGMP‑compliant platform that lets biopharma install continuous manufacturing onsite—cutting capital costs, speeding time‑to‑market, and boosting scalability.

SEA LTD expands in Latin America, gains global tech recognition, and acquires a European firm to boost its consumer‑discretionary tech portfolio—boosting ROI and sustainability in emerging markets.

Indian listed companies, including SEA LTD, close trading windows pre‑quarterly results to curb insider trades—what this means for CapEx, supply chains, and industry tech.

Sea Ltd. splits insurance from finance, forming Religare Finvest to unlock value and meet regulatory goals, while setting the stage for a future re‑merger of Care Health Insurance.

Sea Ltd’s alliance with Proton and Geely boosts Malaysian EV production, doubling plant capacity, cutting cycle‑time and leveraging Geely’s electrification expertise.

Sea Ltd. sees modest share‑price lift as EBITDA stays solid, a new product line gains traction, and cost‑controls drive resilience amid regional softness.

Sea Ltd releases audited 2025‑26 results, highlighting steady CAPEX growth, Industry‑4.0 upgrades and a 2.5 % productivity gain to boost margins and align with India’s infrastructure push.

Sea Ltd’s new small‑molecule dermatology partnership offers milestone cash, rapid regulatory pathways and a $5–$8 bn market upside, but high attrition, IP and supply‑chain risks remain critical.

Sea Ltd expands its critical‑mineral portfolio—Nevada fluorspar, Australia rare‑earth, and Gulf Creek copper‑zinc—to meet strategic supply‑chain needs for AI, batteries, and defense technologies.

Sea Limited’s FY 2025 report reveals how AI, robotics and edge‑computing drive a 18 % platform productivity lift, boosting margins and shaping capital‑expenditure strategy.